ONVO Overview

Partnerships and Innovations: Novo Nordisk has announced a partnership with Nvidia to integrate AI into drug development, alongside a deal with Deep Apple Therapeutics worth up to $812 million for developing drugs targeting cardiometabolic diseases.

Market Concerns: Despite these advancements, Novo's shares have declined 44% over the past year due to concerns about losing its competitive edge in the weight-loss market, prompting the company to seek new innovations and partnerships.

VivoSim Labs Emerges from Stealth Mode: VivoSim Labs has launched its innovative drug discovery methodologies that utilize non-animal testing models, aligning with the FDA's initiative to phase out animal testing. The company aims to disrupt the $10B animal testing market by providing more predictive and ethically sound alternatives.

Transformative Impact on Drug Development: VivoSim's NAMkind models are designed to significantly reduce clinical trial failures and development costs by improving predictions of liver and intestinal toxicity, ultimately leading to safer treatments for patients while addressing challenges faced in current drug evaluation processes.

Company Name Change: Organovo Holdings, Inc. will officially change its name to VivoSim Labs, Inc. on April 24, 2025, with its common stock trading under the new ticker symbol "VIVS" on the Nasdaq Capital Market.

Forward-Looking Statements Disclaimer: The company issued a caution regarding forward-looking statements, highlighting that these are based on current expectations and subject to various risks and uncertainties as detailed in their SEC filings.

argenx SE Stock Surge: Shares of argenx SE rose 5.1% in pre-market trading following FDA approval of VYVGART Hytrulo for self-injection in treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

Pre-Market Stock Movements: Several stocks saw significant changes in pre-market trading, with MSP Recovery, Inc. gaining 167%, while AlTi Global, Inc. experienced a sharp decline of 57.3%.

Financial Overview: Organovo Holdings reported a preliminary cash balance of approximately $11.3 million for the fiscal year ending March 31, 2025, with net cash utilization in the fourth quarter estimated between $2.0 - $2.2 million.

Nasdaq Compliance and Future Milestones: The company expects to meet Nasdaq listing requirements as its stock has been trading above the $1.00 minimum bid price since March 21, 2025, and anticipates receiving a $5 million milestone payment related to a Phase 2 clinical trial for an FXR agonist within the next year.

Financial Overview: Organovo reported a preliminary cash balance of approximately $11.3 million as of March 31, 2025, with a net cash utilization of about $2.0M - $2.2M during the fourth quarter.

Future Expectations: The company anticipates receiving a $5 million milestone payment related to a Phase 2 clinical trial for its FXR agonist within the next year, and expects to meet Nasdaq listing requirements.